Trial · NCT04708886
Adverse events112
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 112
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site reaction | General disorders | Year 1: Romosozumab | 8 | 12 | 14 |
| other | Injection site reaction | General disorders | Year 2: Alendronate | 0 | 12 | 0 |
| other | Bone Pain | Musculoskeletal and connective tissue disorders | Year 1: Romosozumab | 3 | 12 | 3 |
| other | Bone Pain | Musculoskeletal and connective tissue disorders | Year 2: Alendronate | 0 | 12 | 0 |
| other | Urinary tract infection (UTI) | Renal and urinary disorders | Year 1: Romosozumab | 4 | 12 | 5 |
| other | Urinary tract infection (UTI) | Renal and urinary disorders | Year 2: Alendronate | 2 | 12 | 3 |
| other | Burn | Injury, poisoning and procedural complications | Year 1: Romosozumab | 2 | 12 | 2 |
| other | Burn | Injury, poisoning and procedural complications | Year 2: Alendronate | 0 | 12 | 0 |
| other | Wound infection | Skin and subcutaneous tissue disorders | Year 1: Romosozumab | 1 | 12 | 1 |
| other | Wound infection | Skin and subcutaneous tissue disorders | Year 2: Alendronate | 0 | 12 | 0 |
| other | Anisocoria | Eye disorders | Year 1: Romosozumab | 1 | 12 | 1 |
| other | Anisocoria | Eye disorders | Year 2: Alendronate | 0 | 12 | 0 |
| other | Hypotension | Vascular disorders | Year 1: Romosozumab | 1 | 12 | 1 |
| other | Hypotension | Vascular disorders | Year 2: Alendronate | 0 | 12 | 0 |
| other | COVID-19 viral infection | Infections and infestations | Year 1: Romosozumab | 5 | 12 | 5 |
| other | COVID-19 viral infection | Infections and infestations | Year 2: Alendronate | 3 | 12 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Year 1: Romosozumab | 1 | 12 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Year 2: Alendronate | 0 | 12 | 0 |
| other | Spasticity | Nervous system disorders | Year 1: Romosozumab | 2 | 12 | 2 |
| other | Spasticity | Nervous system disorders | Year 2: Alendronate | 0 | 12 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04708886/events